IL-33 Cytokine Therapy for Clostridium difficile Infection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for Clostridium difficile infections are inadequate, with high recurrence rates and mortality, particularly due to the emergence of hypervirulent strains that express an additional toxin, C. difficile transferase (CDT), which exacerbates the severity of the infection and resistance to antibiotics.

Innovation Solution

The use of interleukin-33 (IL-33) as a therapeutic agent to modulate the immune response by stimulating IL-33 expression or administration, either through microbiota transplants or small molecule agonists, to induce regulatory T-cells and reduce inflammation, thereby counteracting the effects of CDT toxin and preventing severe infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If vancomycin or metronidazole treatment is used to fight C. difficile infection, then the infection is inhibited, but the reestablishment of beneficial endogenous flora is inhibited

Engineering Contradiction:

Improveinfection treatment effectivenessVSAvoiddisruption of beneficial endogenous flora

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent uses IL-33 as an intermediary substance that modulates the host immune response to fight C. difficile infection without directly killing bacteria. This mediator approach allows the immune system to clear the pathogen while preserving the natural flora, unlike antibiotics that non-selectively kill both harmful and beneficial bacteria.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces the mechanical/chemical approach of antibiotic killing with an immunological approach using IL-33 cytokine therapy. This substitution shifts from direct bacterial elimination to immune-mediated clearance, which is more selective and preserves beneficial flora.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If antibiotic therapy is used to treat C. difficile infection, then bacterial growth is inhibited, but recurrence rates increase

Engineering Contradiction:

Improveinfection treatment effectivenessVSAvoiddisease recurrence frequency

Core Design Contradiction:

ReliabilityVSDuration of action of stationary object

Solution Approach 1:

IL-33 serves as an immunological mediator that addresses the root cause of recurrence by modulating the host response and restoring microbial balance, rather than simply killing bacteria. This leads to more durable remission by preventing the conditions that allow recurrence.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the therapeutic parameter from antibiotic concentration to IL-33 dosage and timing. This parameter shift enables treatment that modifies the host-pathogen interaction dynamics, reducing recurrence by altering the immune response profile rather than relying on continuous bacterial suppression.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If TLR2 pathway activation occurs in response to CDT toxin, then immune response is mounted, but pro-inflammatory response increases disease severity

Engineering Contradiction:

Improveimmune response activationVSAvoidpro-inflammatory immune response

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent inverts the approach by using IL-33 to activate alternative protective immune pathways that counterbalance the harmful TLR2-mediated inflammation. Instead of blocking TLR2 entirely, it promotes regulatory T-cell responses that oppose the pro-inflammatory effects, effectively inverting the immune response balance.

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent converts the harmful pro-inflammatory response into a beneficial protective response by utilizing IL-33-induced regulatory T-cells. These regulatory cells transform the excessive inflammation into a controlled, protective immune response that fights infection without causing tissue damage.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS10758591B2Compositions and methods for treating clostridium difficile infection

Publication Date: 2020.09.01 UNIV OF VIRGINIA PATENT FOUND

AI summary

Clostridium difficile infection is the leading cause of hospital acquired antibiotic-associated diarrhea in the US (Bartlett, in 2006). The increased prevalence of circulating C. difficile strains poses a significant health threat to US health care facilities. Strains expressing the toxin C. difficile Transferase (CDT), in addition to Toxins A and B (TcdA and TcdB), are more virulent and are associated with higher mortality rates (Bacci et al., 2011). We recently identified a protective role for eosinophils against C. difficile pathogenesis (Buonomo et al., 2016). We have also defined CDT's ability to increase host inflammation and suppress protective eosinophils through a TLR2 dependent mechanism (Cowardin et al., 2016). How CDT promotes virulence and eosinophil suppression via TLR2 is still under investigation. We employed a genome-wide microarray approach to reveal divergent transcriptional profiles between protected (TLR2−/−) and unprotected (WT) mice infected with either CDT expressing or CDT mutant strains of C. difficile. This work revealed novel host mediated TLR2-dependent inflammatory pathways to CDT. We provide an unbiased framework for understanding the host immune response to the binary toxin CDT produced by C. difficile and how TLR2 signaling enhances virulence.